SCHEMBL23405493

SCHEMBL23405493

Oc1ccc(-n2cc(-c3ccc(O)c(O)c3)nn2)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 2/20 0.59
▸ MAPT P10636 2/20 0.59
▸ HSD17B1 P14061 2/20 0.47
▸ HSD17B2 P37059 2/20 0.47
▸ MIF P14174 3/20 0.41
▸ ESRRG P62508 1/20 0.40
▸ CA1 P00915 3/20 0.39
▸ CA2 P00918 3/20 0.39
▸ CA5A P35218 2/20 0.39
▸ CA5B Q9Y2D0 2/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ ESR2 Q92731 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ GFER P55789 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405500 0.85 SNCA (0.61) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL23405471 0.83 SNCA (0.62) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL23405495 0.79 MAPT (0.82) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL23405494 0.78 MAPT (0.81) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL23405479 0.77 MAPT (0.78) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL23405482 0.77 MAPT (0.83) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL2262206 0.76 P2RY14 (0.52) HSD17B1HSD17B2MIFCA12CA9
SCHEMBL23405489 0.76 MAPT (0.78) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL12682333 0.75 SNCA (1.00) SNCAMAPTHSD17B1HSD17B2MIF
SCHEMBL23557576 0.73 MIF (0.50) SNCAMAPTHSD17B1HSD17B2MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 — — US claimed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 — — US claimed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US claimed
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 — — US disclosed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 — — US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 SNCA 4775/4885MAPT 2951/4885HSD17B1 58/4885
US-12297178-B2 Triazole derivative and use thereof FABP4, LIPC, GPR119 SNCA 4771/4885MAPT 2945/4885HSD17B1 54/4885
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 SNCA 4771/4885MAPT 2945/4885HSD17B1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback